TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

Clinical trial NCT06088888 · RECRUITING

Trial details

NCT number: NCT06088888
Sponsor: Shenzhen TargetRx Co., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Chronic Myelogenous Leukemia

Start date: 2024-07-02
Primary completion: 2027-03-30
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.